Dhiraj Gambhire

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Shanu Modi, William Jacot, Toshinari Yamashita et al. · New England Journal of Medicine · 2022 · 2.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Fabrice André, Yeon Hee Park, Sung‐Bae Kim et al. · The Lancet · 2023 · 345 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

Anthony W. Tolcher, Mario Sznol, Siwen Hu‐Lieskovan et al. · Clinical Cancer Research · 2017 · 232 citations

Medicine, Pharmacokinetics, Pharmacology +17

A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V)

Vikas Pai, A Paneerselvam, Satinath Mukhopadhyay et al. · Journal of Diabetes Science and Technology · 2014 · 111 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives

Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire et al. · Diagnostics · 2017 · 56 citations · Full text

Medicine, Molecular Medicine, Oncology +17